Patients with suspected acquired autoinflammatory diseases and autoimmune diseases
Conditions
Interventions
None listed
Sponsors
Yokohama City University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Age 18 years or older 2) No restriction on sex 3) Patients with refractory inflammatory findings or those suspected of having an inflammatory disease by the treating physician 4) Written informed consent obtained for participation in this study
Exclusion criteria
Exclusion criteria: 1) Patients in whom inflammation is clearly attributable to infection or malignancy 2) Patients whose inflammation can be explained by a known inflammatory or autoimmune disease fulfilling established international diagnostic criteria 3) Patients with an expected life expectancy of less than 1 year (e.g., terminal cancer)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival will be defined from the date of study enrollment. Patients alive at the end of follow-up or lost to follow-up after the last confirmed date of survival will be censored. The follow-up period will extend from enrollment to the end of the study. | — |
Secondary
| Measure | Time frame |
|---|---|
| Multi-omics and immunological functional analyses will be performed using specimens from enrolled patients. | — |
Countries
Japan
Contacts
Public ContactYohei Kirino
Yokohama City University Graduate School of Medicine Department of Stem Cell and Immune Regulation
Outcome results
None listed